The U.S. will soon send its unused AstraZeneca COVID-19 vaccines around the world

Signs indicating Oxford-AstraZeneca vaccines are out of stock in India.
(Image credit: INDRANIL MUKHERJEE/AFP via Getty Images)

The United States will soon begin sharing its entire supply of COVID-19 vaccines developed by AstraZeneca and the University of Oxford, the White House told The Associated Press on Monday.

The Oxford-AstraZeneca vaccine has not been granted emergency use authorization by the Food and Drug Administration yet, but White House COVID-19 coordinator Jeff Zients said the country doesn't need the supply at this point, anyway, given "the strong portfolio of vaccines" already available in the country. That includes the shots developed by Johnson & Johnson, Moderna, and Pfizer and BioNTech.

The Biden administration had previously shared about 4 million doses of the Oxford-AstraZeneca vaccine with neighboring Canada and Mexico, but the latest announcement answers calls to expand the strategy further. Per AP, 10 million doses of the vaccine have been produced and are awaiting FDA quality inspection before they can ship out, while 50 million more are in various stages of production and should be good to go by May or June. Read more at The Associated Press.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us